Skip to content
drillr.ai

RLAY

Relay Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$19.18-3.67%

Price as of Jul 20, 2026

RLAY news

Relay Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Relay Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional

    Globe Newswire ·

  2. Relay Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of

    Globe Newswire ·

  3. Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

    Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achieved clinical improvement at week 12, respectively, and support the potential of zovegalisib to drive clinically meaningful benefit for patients Evaluation across a wide dose range confirms potential therapeutic window, with interim safety profil

    Globe Newswire ·

  4. Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

    Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmocic

    Globe Newswire ·

  5. Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

    CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=ams4piWuxQTPxCT8sNCGlcyxhpkrFtY1x99KobOIvxLdwcMeuQ5zPz6Aiq3eagBiWcftsNGyF7llKK4r_2cG5lqiE3dy8GY9Ss2AQ3f_7OE=) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608

    Globe Newswire ·